Citadel Advisors
EIGR

Citadel Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Citadel Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-133
Closed -$898 – 15712
2023
Q4 		$898 Buy
+133
New +$1.17K ﹤0.01% 13920
2023
Q2 		– Sell
-2,343
Closed -$63.1K – 15499
2023
Q1 		$63.1K Sell
2,343
-1,190
-34% -$55.3K ﹤0.01% 11862
2022
Q4 		$125K Buy
3,533
+456
+15% +$54.8K ﹤0.01% 10883
2022
Q3 		$695K Buy
3,077
+1,224
+66% +$301K ﹤0.01% 7759
2022
Q2 		$350K Sell
1,853
-214
-10% -$43.1K ﹤0.01% 9467
2022
Q1 		$515K Buy
+2,067
New +$327K ﹤0.01% 9319
2021
Q3 		– Sell
-767
Closed -$196K – 14891
2021
Q2 		$196K Sell
767
-56
-7% -$14K ﹤0.01% 12183
2021
Q1 		$219K Sell
823
-1,684
-67% -$531K ﹤0.01% 11523
2020
Q4 		$924K Buy
2,507
+644
+35% +$185K ﹤0.01% 6958
2020
Q3 		$455K Buy
+1,863
New +$580K ﹤0.01% 7468
2016
Q1 		– Sell
-11
Closed -$7K – 8223
2015
Q4 		$7K Sell
11
-39
-78% -$22.1K ﹤0.01% 8379
2015
Q3 		$24K Sell
50
-19
-28% -$10.1K ﹤0.01% 8049
2015
Q2 		$39K Buy
69
+59
+590% +$163K ﹤0.01% 7836
2015
Q1 		$87K Buy
+10
New +$87.4K ﹤0.01% 6957

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Citadel Advisors's EIGR Position: Q1 2024 in Review

Citadel Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 334 shares — an estimated $2.25K sold.

Citadel Advisors first reported a position in EIGR in Q1 2015 and held it in 17 quarters. The position peaked at $11.7M in Q4 2020. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

  • Citadel Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 334 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $2.25K.
  • Citadel Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2015 and held it in 17 quarters.
  • Citadel Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $11.7M in Q4 2020.
  • 24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.